ArticleDrug design, development and therapy2014
Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts.
Article in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.Stem cell research & therapy · 2018Pooled it
- The multifaceted roles of mesenchymal stem cell-derived exosomes in digestive system malignancies: mechanisms and therapeutic implications.Frontiers in cell and developmental biology · 2026Review
- Article
- Gastric cancer and mesenchymal stem cell-derived exosomes: from pro-tumorigenic effects to anti-cancer vehicles.Archives of pharmacal research · 2024Review
- The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential.International journal of molecular sciences · 2023Review
- Cell Therapy as Target Therapy against Colon Cancer Stem Cells.International journal of molecular sciences · 2023Review
- Review
- Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications.World journal of stem cells · 2022Review
- Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Mesenchymal stem cells as professional actors in gastrointestinal cancer therapy: From Naïve to genetically modified.Iranian journal of basic medical sciences · 2021Review
- Mesenchymal Stem Cells in Gastric Cancer: Vicious but Hopeful.Frontiers in oncology · 2021Review
- Evaluation of the expression of bone marrow-derived mesenchymal stem cells and cancer-associated fibroblasts in the stroma of gastric cancer tissue.Annals of gastroenterological surgery · 2020Article
- [Progress on utilizing mesenchymal stem cells as cellular delivery system for targeting delivery of as drug/gene for anti-tumor therapy].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2020Review
- Preparation, Characterization, and in vivo Evaluation of NK4-Conjugated Hydroxycamptothecin-Loaded Liposomes.International journal of nanomedicine · 2020Article
- Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.Journal of bone oncology · 2019Review
- Tumor angiogenesis and anti-angiogenic gene therapy for cancer.Oncology letters · 2018Review
- Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment.Frontiers in pharmacology · 2018Review
- Therapeutic effects of adenovirus-mediated CD and NIS expression combined with NaOncology letters · 2017Article
- Genetic engineering of mesenchymal stromal cells for cancer therapy: turning partners in crime into Trojan horses.Innovative surgical sciences · 2016Article
- Synergistic antitumor effect of adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase and nucleoside analogs for human breast carcinoma in vitro and in vivo.Drug design, development and therapy · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) have been recognized as promising delivery vehicles for gene therapy of tumors. Gastric cancer is the third leading cause of worldwide cancer mortality, and novel treatment modalities are urgently needed. NK4 is an antagonist of hepatocyte growth factor receptors (Met) which are often aberrantly activated in gastric cancer and thus represent a useful candidate for targeted therapies. This study investigated MSC-delivered NK4 gene therapy in nude mice bearing gastric cancer xenografts. MSCs were transduced with lentiviral vectors carrying NK4 complementary DNA or enhanced green fluorescent protein (GFP). Such transduction did not change the phenotype of MSCs. Gastric cancer xenografts were established in BALB/C nude mice, and the mice were treated with phosphate-buffered saline (PBS), MSCs-GFP, Lenti-NK4, or MSCs-NK4. The tropism of MSCs toward gastric cancer cells was determined by an in vitro migration assay using MKN45 cells, GES-1 cells and human fibroblasts and their presence in tumor xenografts. Tumor growth, tumor cell apoptosis and intratumoral microvessel density of tumor tissue were measured in nude mice bearing gastric cancer xenografts treated with PBS, MSCs-GFP, Lenti-NK4, or MSCs-NK4 via tail vein injection. The results showed that MSCs migrated preferably to gastric cancer cells in vitro. Systemic MSCs-NK4 injection significantly suppressed the growth of gastric cancer xenografts. MSCs-NK4 migrated and accumulated in tumor tissues after systemic injection. The microvessel density of tumor xenografts was decreased, and tumor cellular apoptosis was significantly induced in the mice treated with MSCs-NK4 compared to control mice. These findings demonstrate that MSC-based NK4 gene therapy can obviously inhibit the growth of gastric cancer xenografts, and MSCs are a better vehicle for NK4 gene therapy than lentiviral vectors. Further studies are warranted to explore the efficacy and safety of the MSC-based NK4 gene therapy in animals and cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.